Nabi up on smoking cessation data

NABI was up $1.79 (15%) to $13.48 on 4.6 million shares on Tuesday after results from a 68-patient Phase II trial showed patients receiving 200 ug of its NicVAX nicotine conjugate vaccine had a 33% qu...